Glioblastoma Multiforme Treatment Market to Surge 10.1% Growth Expected 2022-2032

In 2021, the Glioblastoma Multiforme Treatment Market reached a valuation of US$2.6 billion, and it is expected to undergo significant growth from 2022 to 2032, surpassing the historical growth rate with a projected 10.1% increase. Glioblastoma Multiforme (GBM) is a highly aggressive and lethal form of brain cancer, posing a substantial global healthcare challenge. The market is dedicated to developing therapeutic solutions, offering hope to patients grappling with this devastating disease. As of 2022, the market's value stood at approximately $2.1 billion, exhibiting a compound annual growth rate (CAGR) of 12.5% over the last five years. This growth is fueled by factors such as the rising incidence of GBM, increased focus on research and development, and advancements in treatment options.

Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7187

Market Opportunity:

The Glioblastoma Multiforme Treatment Market offers significant opportunities for growth and innovation. These opportunities include the exploration of novel therapeutic approaches, such as immunotherapies, targeted therapies, and precision medicine, to meet the demand for more effective and less toxic treatments. Additionally, the expanding target population, driven by the increasing incidence of GBM and an aging demographic, provides a chance for heightened market penetration. Furthermore, investment in research and development for innovative therapies, biomarkers, and diagnostics can pave the way for personalized GBM treatment, offering companies a competitive advantage.

Market Challenges:

GBM poses a significant challenge due to its notorious treatment resistance, necessitating extensive research and innovative approaches for the development of effective therapies. The high development costs in the oncology sector, characterized by substantial financial investments in clinical trials and regulatory approvals, present a hurdle for companies. Stringent regulatory requirements and complex approval processes further impede the timely introduction of innovative therapies, requiring companies in the GBM market to navigate these obstacles to bring new treatments to patients.

Key Players:

Merck & Co., Inc.
Amgen, Inc.
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Amgen, Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Arbor Pharmaceuticals, LLC
Amneal Pharmaceuticals
Karyopharm Therapeutics, Inc.
Sumitomo Dainippon Pharma Oncology, Inc.

Competitive Landscape:

Leading companies in the glioblastoma multiforme treatment market are strategically prioritizing research and development (R&D) initiatives to secure a competitive advantage. They are also actively engaging in mergers, acquisitions, licensing agreements, and collaborations to broaden their product portfolios, bolster manufacturing capabilities, and establish a distinctive competitive position.

Recent advancements in glioblastoma multiforme treatment include:

In April 2021, Lineage Cell Therapeutics entered a licensing agreement with Immunomic Therapeutics to develop allogeneic VAC, a cancer immunotherapy platform, specifically targeting glioblastoma multiforme. The agreement involves an upfront payment of US$2 million for Lineage, with an additional US$67 million in commercial milestone payments.

In July 2020, Denovo Biopharma, a San Diego-based biotech company, gained approval from the U.S. Food & Drug Administration (FDA) for its phase 2b clinical trial. This trial aims to assess an analytical combination therapy for newly diagnosed glioblastoma multiforme patients.

In May 2019, Merck announced its acquisition of Peloton Therapeutics, providing access to the experimental glioblastoma drug PT2977. This strategic move is anticipated to fortify Merck's pipeline and enhance its future revenue-generating capabilities.

These developments underscore the proactive efforts of key providers in the glioblastoma multiforme treatment sector to advance innovative therapies and broaden their market presence.

Market Segments Covered in Glioblastoma Multiforme Treatment Market Analysis

By Treatment :
Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Tumor Treating Field (TTF) Therapy
Immunotherapy

By Drug Class :
Temozolomide
Bevacizumab
Carmustine Wafers
Other Drug Classes
Lomustine

By Application :
Hospitals
Clinics
Ambulatory Surgical Centers

By Region :
North America
Latin America
Europe
APAC
MEA

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=7187

Contact:

US Sales Office

11140 Rockville Pike

Suite 400 Rockville, MD 20852

United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)

Sales Team: sales@factmr.com

About Fact.MR :

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.